KSTAR also correctly predicted that a clinically diagnosed HER2-negative PDX model would be responsive to EGFR/HER2 therapy, suggesting that phosphoproteomics combined with KSTAR can offer an orthogonal clinical diagnostic for breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.